National breast cancer clinical study rolled out
It follows research funded by the Irish Cancer Society and Health Research Board, which found that women prescribed aspirin regularly before a diagnosis were less likely to have cancer that spread to the lymph nodes.
Breast-Predict researchers will now investigate how aspirin may improve breast cancer outcomes and, to do this, information on exposure to the medicine will be gathered from almost 3,000 patients around the country.
Patients will be asked to answer questions on their recent exposure to aspirin.
Laboratory-based studies will also be conducted.
The study was announced at the launch in Dublin yesterday of the Irish Cancer Society’s new Paint it Pink campaign to raise money to fight against breast cancer.
The study is one of a number run by the national cancer clinical research organisation, the All Ireland Co-operative Oncology Research Group (ICORG).
The Irish Cancer Society also provides core funding to ICORG every year to allow clinical trials to take place in the area of breast and other cancers.
Breast-Predict researchers can now access tumour and serum samples from over 1,000 patients for their research studies through ICORG clinical trials.
The Irish Cancer Society’s CEO, John McCormack, said they could not continue their work in the fight against cancer without raising significant funds.
*
#PinkPics for the Paint it Pink by the Irish Cancer Society http://t.co/i50ajxaxzA http://t.co/A97DBBXLHk
— Irish Cancer Society (@IrishCancerSoc) September 3, 2014
